|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | 0.00% |
|
+4.65% | -61.76% |
| 30/06 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 30/06 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
| Market Cap | 17Cr 15Cr 14Cr 13Cr 24Cr 1.65TCr 25Cr 165.5Cr 65Cr 809.85Cr 64Cr 63Cr 2.79TCr | P/E 2026 * |
-1.58x | P/E 2027 * | -2.04x |
|---|---|---|---|---|---|
| Enterprise Value | 17Cr 15Cr 14Cr 13Cr 24Cr 1.65TCr 25Cr 165.5Cr 65Cr 809.85Cr 64Cr 63Cr 2.79TCr | EV / Sales 2026 * |
2.12x | EV / Sales 2027 * | 1.39x |
| Free-Float |
83.84% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ADC Therapeutics SA
| 1 week | +4.65% | ||
| Current month | +26.17% | ||
| 1 month | +23.85% | ||
| 3 months | -68.46% | ||
| 6 months | -62.71% | ||
| Current year | -61.76% |
| 1 week | 1.21 |  | 1.46 |
| 1 month | 1 | | 1.46 |
| Current year | 0.78 | | 4.98 |
| 1 year | 0.78 | | 4.98 |
| 3 years | 0.36 | | 6.04 |
| 5 years | 0.36 | | 32 |
| 10 years | 0.36 | | 56.59 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ameet Mallik
CEO | Chief Executive Officer | 53 | 09/05/2022 |
Jose Carmona
DFI | Director of Finance/CFO | 54 | 19/12/2022 |
David Ege
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 59 | 01/06/2025 |
Peter Hug
BRD | Director/Board Member | 67 | 01/06/2019 |
Ron Squarer
CHM | Chairman | 59 | 01/03/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 30/06/26 | Free | Chief Executive Officer | 6,75,000 | 0.5307% | ||
| 30/06/26 | Free | Chief Technology Officer | 2,13,900 | 0.1682% | ||
| 30/06/26 | Free | Chief Financial Officer | 2,03,700 | 0.1602% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +4.65% | -55.45% | -10.00% | 17Cr | |
| +0.24% | -1.54% | +52.85% | +71.85% | 5.38TCr | |
| -7.17% | -4.39% | +42.72% | +73.32% | 5.21TCr | |
| +0.80% | -6.31% | +5.62% | +417.78% | 2.35TCr | |
| -0.09% | -0.01% | -16.85% | -15.41% | 2.31TCr | |
| -5.95% | -2.58% | +29.53% | -9.47% | 1.94TCr | |
| -1.14% | +0.03% | +31.67% | -30.65% | 1.76TCr | |
| -5.16% | -7.00% | +168.44% | +314.96% | 1.52TCr | |
| -6.91% | -5.83% | +25.17% | +644.30% | 1.48TCr | |
| +0.43% | -1.03% | +25.75% | +189.74% | 1.41TCr | |
| Average | -2.50% | -1.90% | +30.94% | +164.64% | 2.34TCr | |
| Weighted average by Cap. | -2.80% | -2.35% | +39.48% | +143.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.09Cr 7.07Cr 6.52Cr 6.01Cr 11Cr 778.99Cr 12Cr 78Cr 31Cr 381.52Cr 30Cr 30Cr 1.31TCr | 12Cr 11Cr 9.98Cr 9.2Cr 17Cr 1.19TCr 18Cr 119.34Cr 47Cr 583.97Cr 46Cr 45Cr 2.01TCr |
| Net income | -14Cr -12Cr -11Cr -10Cr -19Cr -1.31TCr -19Cr -131.21Cr -52Cr -642.05Cr -51Cr -50Cr -2.21TCr | -12Cr -10Cr -9.46Cr -8.72Cr -16Cr -1.13TCr -17Cr -113.08Cr -44Cr -553.32Cr -44Cr -43Cr -1.9TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | $1.350 | 0.00% | 13,31,582 |
| 16/26/16 | $1.350 | +5.47% | 9,57,727 |
| 15/26/15 | $1.280 | +4.07% | 5,49,729 |
| 14/26/14 | $1.230 | -1.60% | 6,99,106 |
| 13/26/13 | $1.250 | -3.10% | 6,35,107 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADCT Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
